Margarida Maia, PhD,  science writer—

Dosing has started in the first group of healthy adults participating in a clinical study of S-1117, a candidate treatment Seismic Therapeutic designed to break down harmful self-reactive antibodies in autoimmune diseases like myasthenia gravis (MG). Running at a single site in Australia, the Phase 1 clinical…

Tacrolimus, an immunosuppressant sometimes used off-label to treat adults with myasthenia gravis (MG), eased symptoms of the disease in about four in every five children with juvenile MG, with few side effects. That’s according to a meta-analysis of nine studies from China and Japan, which also found tacrolimus…

People with more severe myasthenia gravis (MG) have a greater likelihood of experiencing episodes of exacerbation, when symptoms worsen or reappear, and may need more medical care, according to the findings of a new study. The study also suggested that personalized treatment for these MG patients may ease the…

Myasthenia gravis (MG) may be more likely to begin manifesting in the summer, with the onset of symptoms more common in hotter weather, according to a new study by researchers in Italy. The team theorized that the increased incidence of MG may occur because temperatures at that time of…

The COVID-19 pandemic caused emotional challenges for many people with myasthenia gravis (MG) in Australia, but how well their disease was treated or how well  their symptoms were kept under control weren’t affected, a survey study finds. “As we continue to live with COVID-19, clinicians should consider its various…

Enspryng (satralizumab), tested by Chugai Pharmaceutical as a treatment for generalized myasthenia gravis (gMG), eased disease symptoms and made daily life easier when used in addition to standard of care therapy over six months, but its clinical benefit was somewhat limited. These data from LUMINESCE (NCT04963270), a…

People who are genetically predisposed to myasthenia gravis (MG) are more likely to develop Graves’ disease and Hashimoto’s thyroiditis, two autoimmune diseases of the thyroid gland, according to a study in China. Researchers also found a genetic link in the opposite direction, where being genetically predisposed to Graves’ disease…

Cyrus Biotechnology has selected CYR212 as its clinical development candidate for myasthenia gravis (MG) and other autoimmune diseases driven by immunoglobulin G (IgG) self-reactive antibodies, the company announced in a press release. According to the U.S.-based biotech, CYR212’s profile — as seen in preclinical data culled from…

Many adults with myasthenia gravis (MG) need intensive treatment in the first year after diagnosis, with younger patients and women facing a higher risk of death as the disease progresses, a study found. The researchers said the results point to a need for better treatment options. The study, “…

The healthcare costs of myasthenia gravis (MG) are high, according to a study from Denmark, Finland, and Sweden, and even higher for women and patients with very severe symptoms or coexisting conditions such as mental health problems or severe infections. A large portion of direct costs in all three…